|
Instinkt, 5 June 2025 ‘Research leading to new treatments in oncology but also in medicine in general follows basically two distinct paths. One takes the form of improvements on the existing “weaponry” and a search for “new roles for old friends”. The other is more revolutionary, based on new findings: it aims at new targets, which we look for not just in individual cells but in a wider context’, says NICR Director Aleksi Šedo. |
|
CNN Prima News, 22 June 2025 Scientists from the Laboratory of cellular communication of the Faculty of Science of the Masaryk University, which is part of NICR, in collaboration with the Laboratory of organic synthesis and medicinal chemistry and the University Hospital Brno, have been developing and testing a new class of substances for the treatment of resistant acute myeloid leukaemia and other cancers. The newly discovered compounds successfully suppress the activity of casein kinase 1. This project takes place in close collaboration with the MU CasInvent Pharma spin-off company. |
|
Seznam Zprávy, 4 July 2025 ‘For most metastatic tumours, targeted treatment or immunotherapy are nowadays part of recommended therapy. My role as a molecular biologist and geneticist rests mainly in advanced tumour diagnostics. Thanks to it, we can find in the tumour damaged genes, which can then be targeted by a treatment. The technological advances that took place in this area over the past decade are incredible,’ says, among other things, Ondřej Slabý. |
|
Lead Stories, 14 July 2025 There is no trustworthy scientific research confirming any link between vaccines, including those that use mRNA technologies, and a higher occurrence of cancers in the population in general or among younger people specifically. ‘No serious scientific research has confirmed a link between vaccination and an increased incidence of cancer or autism,’ emphasises NICR Director Aleksi Šedo in his commentary. ‘On the contrary, some vaccines, for instance against HPV or hepatitis B, protect against cancer.’ |
|
Medical Tribune, 6 August 2025 Platelets numbers, concentration of C-reactive protein, and chromogranin A levels are three indicators which are important but can easily be obtained from a blood sample. They indicate a failure of combined hormonal treatment of prostate cancers. The results of a study conducted by researchers from the Laboratory of molecular pathology at the Institute of Clinical and Molecular Pathology of the Faculty of Medicine of Palacký University, which is part of NICR, the Institute of Molecular and Translational Medicine of the Faculty of Medicine of Palacký University and the University Hospital Olomouc, and of the Oncology Department of the Faculty of Medicine of Palacký University and the University Hospital Olomouc, were published by the Journal of Molecular Diagnostics. |
|
DOTYK, 12 August 2025 In order to survive, cancer cells send each other messages. ‘Cancer cells use extracellular vesicles to spread misinformation and create the so-called cancer micro-environment. In this way, they can suppress the immune response, create inflammatory lesions which support tumour growth, stimulate the formation of new veins, or share information about how to resist anti-tumour treatment,’ explains Markéta Bocková from the Institute of Photonics and Electronics of the CAS. |
|
Český rozhlas, Věda Plus, 12 August 2025 The team of Marek Mráz, head of the Microenvironment of Immune Cells at the CEITEC MU, which is part of NICR, had discovered how the most common type of leukaemia in adults can adapt to treatment. The researchers were the first in the world to describe a non-genetic mechanism which leukaemia cells use to open an alternative signalling pathway using the Fox01 protein. This enables them to continue in uncontrolled growth and division. Scientists in Brno had also started to test a substance that could prevent this process. |
|
Český rozhlas Radiožurnál, Magazín Experiment, 6 September 2025 How could we deliver an anti-tumour drug right into a cancer cell and then prevent that cell from becoming resistant to that therapy? Scientists from the Laboratory of tumour immunology of the Institute of Microbiology of the CAS and the department of Biomedical polymers of the Institute of Macromolecular Chemistry of the CAS, which are both members of the NICR, came up with new answers to these questions. Their new nanosystem not only helps to deliver a therapeutic substance into the tumour but also prevents the drug from being eliminated. Tests in cell cultures and animal models have shown that, when this system was used, therapy resistant cancer cells have accumulated multiple times more drug than controls. |
